Triple Play Biotech Firm: Sunshine Biopharma (Stock Symbol: SBFM) Pays Off Convertible Notes in Cash Preventing New Shares from Hitting the Market 1

SBFM has paid off just over $100,000 worth of convertible notes associated with the Company. Our Board of Directors deemed this action to be a priority for the Company in order to mitigate dilutive conversions and maximize shareholder value.

  • Biopharma Company with Worldwide Patents on Effective Cancer Drugs.  

  • Joint Agreement to Advance Cancer Treatment to Clinical Trials in Canada. 

  • New Distribution of Nutritional Supplements in Asia and the Far East. 

  • Developing New Anti-Coronavirus Drug with the University of Georgia. 

  • $2 Million Financing in Place to Support Anti-Coronavirus Program. 


Sunshine Biopharma (OTC:
SBFM) is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, SBFM is engaged in the development and commercialization of science-based nutritional supplements and is also currently engaged in the development of a new pharmaceutical to treat infections of the Covid-19 Coronavirus.  

Since inception, SBFM has been involved in the development of Adva-27a, a small molecule that has been shown to be exceptionally effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). SBFM is a direct owner of all worldwide patents covering Adva-27a, including all issued and pending patents. 

  • Agreement with a Montreal-based Company to Advance the Highly Promising Development of Adva-27a Anticancer Compound

On November 18th SBFM announced a collaboration agreement with a Montreal-based company for the purposes of advancing the development of the SBFM anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture. Based on the cell culture results, the SBFM drug development partner will conduct mice studies in preparation for entry of Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University’s Jewish General Hospital in Montreal, Canada.

  • Distribution of High Value Essential-9(TM) in Asia and the Far East

On November 10th SBFM announced an agreement with JOAH International Pte., Ltd., headquartered in Singapore, for distribution of Essential-9tm in Asia and the Far East. The SBFM Essential-9tm is a nutritional supplement tablet comprised of a balanced formula of the 9 essential amino acids that the human body cannot make. Essential-9tm is authorized for marketing by Health Canada under NPN 80089663. 

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, chronic fatigue, weight gain, and weakened immune system. The SBFM Essential-9TM provides a balanced formula of all 9 Essential Amino Acids in free-form, ready to be absorbed. Essential-9tm is suitable for everyone: Vegans, Seniors, Dieters, Athletes, and everyone looking to increase their health. In North America, Essential-9tm is available on  Amazon.com and Amazon.ca.

  • Sunshine Biopharma and the University of Georgia Team Up to Develop New and Vitally Needed Anti-Coronavirus Drug

On October 19th SBFM announced an agreement with the University of Georgia to advance the development of the company’s recently announced Anti-Coronavirus lead compound, SBFM-PL4. The goal of this cutting-edge collaboration is to develop SBFM-PL4, a protease inhibitor, as a treatment for Coronavirus infections. This new treatment is based on the technology described in recently filed SBFM patent application covering small molecules which can be used to treat Coronavirus infections. Sunshine’s SBFM-PL4, will be put through a series of in vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture testing stage and assessment in Coronavirus infected mice before entering human clinical trials.

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the current pandemic. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22nd SBFM filed a provisional patent application for a library of molecules which were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness.

  • Sunshine Biopharma Secures $2,000,000 + Financing for Critical Coronavirus Treatment

On September 15th SBFM announced that it has received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc. Under the agreement RB Capital has agreed to provide funding to SBFM in the form of convertible promissory notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of the Company’s Common Stock at a conversion price equal to the market value on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. SBFM reserves the right to pay off any part or all of the Promissory Notes at any time without penalty. The minimum amount of funding that RB Capital has agreed to provide to SBFM under these terms is $2,000,000, payable over the next three to six-month period.

For more information on Sunshine Biopharma (OTC: SBFM) visit: http://www.sunshinebiopharma.com

Media Contact
Company Name: SUNSHINE BIOPHARMA INC
Contact Person: Media Relations
Email: Send Email
Phone: (514) 426-6161
Address:6500 Trans-Canada Highway 4th Floor
City: Pointe-Claire
State: QC H9R 0A5
Country: Canada
Website: www.sunshinebiopharma.com